Beta-Blocker Pretreatment Does Not Affect the Renoprotective Effects of Low-Dose Dopamine in Patients with Acute Decompensated Heart Failure

Positive inotropes in heart failure: a review article

“…Dopamine may exert this effect without significantly improving creatinine clearance 11. This effect is not generally affected by chronic β blocker use, which is the case in most decompensated heart failure patients,12 but may be blunted by haloperidol and other butyrophenones 13. Ibopamine, a dopamine agonist that stimulates the dopaminergic-1 and dopaminergic-2 receptors resulting in peripheral and renal vasodilatation, improved heart failure symptoms during a short-term use,14 but was associated with increased mortality in the PRIME-II trial, which evaluated 1906 patients with severe (New York Heart Association (NYHA) class III and IV) heart failure who were already receiving maximal medical therapy (25% vs 20% for placebo at approximately 1 year) 15.…”